The aim of this review is to provide an up-to-date overview of treatment approaches for systemic lupus erythematosus (SLE), highlighting the multiplicity and heterogeneity of clinical symptoms that underlie therapeutic decisions. Discussion will focus on the spectrum of currently available therapies, their mechanisms and associated side-effects. Finally, recent developments with biologic treatments including rituximab, epratuzumab, tumor necrosis factor (TNF) inhibitors, and belimumab, will be discussed.
Limited evidence suggests that supplementation may be clinically beneficial in SLE patients with low levels of vitamin D. In Mediterranean patients, female patients who were not receiving supplemental vitamin D showed more fatigue and received more oral corticosteroids than those with normal levels of vitamin D.  In Australian patients, an increase in serum vitamin D levels was associated with reduced disease activity over time. 
One food to avoid is alfalfa sprouts. Alfalfa tablets have been associated with lupus flares or a lupus-like syndrome that includes muscle pain, fatigue, abnormal blood test results, and kidney problems. These problems may be due to a reaction to an amino acid found in alfalfa sprouts and seeds. This amino acid can activate the immune system and increase inflammation in people with lupus. Garlic may also stimulate the immune system.
Mercury is toxic to our bodies and can be one piece of the puzzle for those with lupus and other chronic illnesses such as chronic fatigue syndrome, other autoimmune diseases, neurological disorders, and cancer. Mercury overload is far more common than many people think. We’re exposed to mercury in our air and water, the fish we eat, amalgam fillings, cosmetics, and vaccines. I recommend heavy metal testing for all of my patients with autoimmunity, using a pre- and post-DMPS urine challenge test. I also recommend that anyone with mercury amalgam fillings find a biological dentist and have them removed.
16α-OH 16α-hydroxyestrone; 2-OH 2-hydroxyestrone; Akt protein kinase B; BAFF B-cell activating factor; EGCG epigallocatechin gallate; ER oestrogen receptor; EVOO extra virgin olive oil; FOXP3 forkhead box P3; I3C indole-3-carbinol; IFN interferon; LPS lipopolysaccharide; MRL Murphy Roths large; NZB/W New Zealand black/white; Nrf-2 nuclear factor E2-related factor 2; SLE systemic lupus erythematosus; Th T-helper; Treg regulatory T-cell; dsDNA double-stranded DNA; ppm parts per million; Diet; Immunomodulation; Lupus; Nutrients; Systemic lupus erythematosus
Although these guidelines consider region limitations, the inclusion of alternative approaches for tailoring treatment did not exclude the task of providing physicians with the state-of-the-art findings in the field. This was a major advantage of the present work since highlighting these advances provides valuable basis for future requirement of government authorisation of new drugs in these countries.
Unfortunately, significant side effects are associated with cyclophosphamide-based regimens, which are the only ones with proven long-term efficacy. An alternative consideration is mycophenolate mofetil, which may be as effective as pulse cyclophosphamide but with less severe adverse effects. In refractory cases (lack of treatment response by 6 months), consider intensifying therapy with mycophenolate mofetil. 
Since a large percentage of people with SLE have varying amounts of chronic pain, stronger prescription analgesics (painkillers) may be used if over-the-counter drugs (mainly nonsteroidal anti-inflammatory drugs) do not provide effective relief. Potent NSAIDs such as indomethacin and diclofenac are relatively contraindicated for people with SLE because they increase the risk of kidney failure and heart failure.
Painless passage of blood or protein in the urine may often be the only presenting sign of kidney involvement. Acute or chronic renal impairment may develop with lupus nephritis, leading to acute or end-stage kidney failure. Because of early recognition and management of SLE, end-stage renal failure occurs in less than 5% of cases; except in the black population, where the risk is many times higher.
Since SLE patients can have a wide variety of symptoms and different combinations of organ involvement, no single test establishes the diagnosis of systemic lupus. To help doctors improve the accuracy of the diagnosis of SLE, 11 criteria were established by the American Rheumatism Association. These 11 criteria are closely related to the symptoms discussed above. Some people suspected of having SLE may never develop enough criteria for a definite diagnosis. Other people accumulate enough criteria only after months or years of observation. When a person has four or more of these criteria, the diagnosis of SLE is strongly suggested. Nevertheless, the diagnosis of SLE may be made in some settings in people with only a few of these classical criteria, and treatment may sometimes be instituted at this stage. Of these people with minimal criteria, some may later develop other criteria, but many never do.
Other diseases and conditions that can accompany lupus include fibromyalgia, coronary heart disease, nonbacterial valvular heart disease, pancreatitis, esophagus disease with difficulty swallowing (dysphagia), swollen lymph nodes (lymphadenopathy), liver disease (lupoid hepatitis), infections, and a tendency to spontaneous blood clotting and thrombosis.
An abnormal elevation of temperature. The normal temperature taken orally ranges from about 97.6° to 99.6°F (36.3°C to 37.6°C). Rectal temperature is 0.5° to 1.0°F higher than oral temperature. Normal temperature fluctuates during the day and is lowest in the morning and highest in the late afternoon; these variations are maintained during a fever. The expended basal energy is estimated to be increased about 12% for each degree centigrade of fever.
The removal of plasma from a patient (usually to treat an immmunologically mediated illness such as thrombotic thrombocytopenic purpura or myasthenia gravis) and its replacement with normal plasma. Plasma exchange therapy can also be used to replace excessively viscous plasma in patients with Waldenström macroglobulinemia. Pathological antibodies, immune complexes, and protein-bound toxins are removed from the plasma by plasma exchange. Immunoglobulin infusions are an alternative to plasma exchange when treating some immunological illnesses, including Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy.
No single finding qualifies an individual as having SLE. Instead, the American College of Rheumatology (ACR) has devised certain classification criteria, and four or more of these criteria must be present for a classification of lupus. [The term “classification” is not synonymous with “diagnosis.” “Classification” means that reasonable certainty exists for the diagnosis of lupus for research purposes.] Although, these criteria are currently being updated, they are believed to be about 90% effective. The ACR criteria include malar rash; discoid rash; photosensitivity (development of a rash after sun exposure); oral or nasal ulcers; arthritis of multiple joints; serositis: (inflammation of the lining around the lungs or heart); kidney disease indicated by protein or casts in the urine; neurological disorders such as seizures and psychosis; and blood disorders such as hemolytic anemia, leukopenia, and lymphopenia. Other signs that are common but not included in the classification criteria are hair loss or breaking, especially around the forehead, and Raynaud’s Phenomenon, a two- or three-color change of the fingertips upon cold exposure.
Some patients with mild lupus, with a little joint pain or rash can be managed with anti-inflammatory drugs such as nonsteroidal anti-inflammatory drugs, or NSAIDs, such as ibuprofen or naproxen, says Stuart D. Kaplan, MD, the chief of rheumatology at South Nassau Communities Hospital in Oceanside, New York. These drugs can also help manage fever and inflammation of the heart and lining around the lungs. (2)
Affiliate Disclosure: There are links on this site that can be defined as affiliate links. This means that I may receive a small commission (at no cost to you) if you purchase something when clicking on the links that take you through to a different website. By clicking on the links, you are in no way obligated to buy.
Please Note: The material on this site is provided for informational purposes only and is not medical advice. Always consult your physician before beginning any diet or exercise program.
Copyright © livehopelupus.org